NeuroOne Medical Technologies (NASDAQ:NMTC) Insider David Wambeke Buys 33,333 Shares of Stock

NeuroOne Medical Technologies Corporation (NASDAQ:NMTC) insider David Wambeke acquired 33,333 shares of NeuroOne Medical Technologies stock in a transaction on Thursday, August 27th. The shares were bought at an average cost of $2.01 per share, for a total transaction of $66,999.33. Following the completion of the purchase, the insider directly owned 199,999 shares of the company’s stock, valued at $401,997.99. The trade was a 20.00% increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

NeuroOne Medical Technologies Price Performance

NASDAQ:NMTC opened at $1.69 on Wednesday. The firm has a market capitalization of $15.40 million, a price-to-earnings ratio of -1.78 and a beta of 0.65. NeuroOne Medical Technologies Corporation has a 1 year low of $1.42 and a 1 year high of $6.96. The business has a 50 day simple moving average of $2.06 and a 200-day simple moving average of $3.42.

NeuroOne Medical Technologies (NASDAQ:NMTC) last released its earnings results on Thursday, August 13th. The company reported ($0.28) earnings per share for the quarter, missing the consensus estimate of ($0.21) by ($0.07). NeuroOne Medical Technologies had a negative net margin of 71.50% and a negative return on equity of 128.12%. The company had revenue of $1.97 million for the quarter, compared to the consensus estimate of $2.17 million. As a group, analysts expect that NeuroOne Medical Technologies Corporation will post -0.39 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities research analysts have recently weighed in on the stock. Maxim Group set a $5.00 target price on shares of NeuroOne Medical Technologies and gave the company a “buy” rating in a research note on Friday, August 14th. LADENBURG THALM/SH SH upped their price target on shares of NeuroOne Medical Technologies from $1.60 to $8.00 and gave the company a “buy” rating in a report on Wednesday, May 13th. Finally, Weiss Ratings lowered shares of NeuroOne Medical Technologies from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Friday, August 21st. Three analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the stock currently has an average rating of “Hold” and an average price target of $7.33.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of the company. Legato Capital Management LLC purchased a new position in NeuroOne Medical Technologies during the 4th quarter worth $34,000. Squarepoint Ops LLC purchased a new stake in shares of NeuroOne Medical Technologies in the 4th quarter worth $36,000. Susquehanna International Group LLP bought a new position in shares of NeuroOne Medical Technologies during the 2nd quarter worth $41,000. XTX Topco Ltd bought a new position in shares of NeuroOne Medical Technologies during the 2nd quarter worth $51,000. Finally, BlackRock Inc. purchased a new position in shares of NeuroOne Medical Technologies during the second quarter valued at $76,000. Institutional investors own 16.07% of the company’s stock.

About NeuroOne Medical Technologies

NeuroOne Medical Technologies Corp. is a medical device company focused on developing advanced neural interface technologies for diagnostic and therapeutic applications in neurosurgery and neurology. The company’s core mission is to improve patient outcomes through next-generation electrode systems that enable high-resolution neural recording and targeted stimulation. By leveraging proprietary thin-film microelectrode arrays, NeuroOne aims to offer clinicians unprecedented single-unit precision during brain mapping procedures.

The company’s flagship platform, the EVO™ system, integrates thin-film neural electrodes with intraoperative monitoring hardware and software.